Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Buy
56
GILD Quote, Financials, Valuation and Earnings
Last price:
$93.89
Seasonality move
:
5.42%
Day range:
$92.10 - $94.05
52-week range:
$62.07 - $98.90
Dividend yield:
3.28%
P/E ratio:
1,043.89x
P/S ratio:
4.16x
P/B ratio:
6.34x
Volume:
2.1M
Avg. volume:
7.5M
1-year change:
17.94%
Market cap:
$117.1B
Revenue:
$27.1B
EPS (TTM):
$0.09
Analysts' Opinion
-
Consensus RatingGilead Sciences has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 12 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $98.92, Gilead Sciences has an estimated upside of 5.29% from its current price of $93.95.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $73.00 representing 100% downside risk from its current price of $93.95.
Fair Value
-
According to the consensus of 25 analysts, Gilead Sciences has 5.29% upside to fair value with a price target of $98.92 per share.
GILD vs. S&P 500
-
Over the past 5 trading days, Gilead Sciences has underperformed the S&P 500 by -1.66% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Gilead Sciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Gilead Sciences has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Gilead Sciences reported revenues of $7.5B.
Earnings Growth
-
Gilead Sciences earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Gilead Sciences reported earnings per share of $1.00.
Enterprise value:
135.2B
EV / Invested capital:
3.25x
Price / LTM sales:
4.16x
EV / EBIT:
116.87x
EV / Revenue:
4.78x
PEG ratio (5yr expected):
--
EV / Free cash flow:
14.34x
Price / Operating cash flow:
12.47x
Enterprise value / EBITDA:
34.50x
Gross Profit (TTM):
$21.5B
Return On Assets:
0.22%
Net Income Margin (TTM):
0.45%
Return On Equity:
0.64%
Return On Invested Capital:
0.29%
Operating Margin:
41.66%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $27.1B | $27.4B | $28.3B | $7.1B | $7.5B | |
| Gross Profit | $20.2B | $21.6B | $21.5B | $5.5B | $6B | |
| Operating Income | $7.5B | $11.9B | $7.6B | $2.7B | $3.1B | |
| EBITDA | $7.6B | $10.7B | $3.9B | $3.2B | $1.9B | |
| Diluted EPS | $2.65 | $4.66 | $0.09 | $1.73 | $1.00 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $30.9B | $14B | $13.6B | $16B | $14.8B | |
| Total Assets | $60.9B | $67.1B | $62.6B | $62.4B | $54.5B | |
| Current Liabilities | $9.5B | $10.2B | $10.4B | $11.9B | $11.7B | |
| Total Liabilities | $43.4B | $45.6B | $41.5B | $40.1B | $36.1B | |
| Total Equity | $17.5B | $21.5B | $21.1B | $22.2B | $18.4B | |
| Total Debt | $29.3B | $27.7B | $25.2B | $25B | $23.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $9.7B | $8.4B | $10B | $1.8B | $4.3B | |
| Cash From Investing | -$2.4B | -$1.9B | -$4B | -$229M | -$710M | |
| Cash From Financing | -$6.9B | -$5.6B | -$6.8B | -$1.5B | -$1.4B | |
| Free Cash Flow | $9B | $7.9B | $9.4B | $1.6B | $4.2B | |
GILD
Sector
Market Cap
$117.1B
$46.1M
Price % of 52-Week High
95%
46.02%
Dividend Yield
3.28%
0%
Shareholder Yield
4.68%
-0.6%
1-Year Price Total Return
17.94%
-30.52%
Beta (5-Year)
0.175
0.772
Dividend yield:
3.28%
Annualized payout:
$3.00
Payout ratio:
3085.71%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$92.30
200-day SMA
Buy
Level
$77.11
Bollinger Bands (100)
Buy
Level
78.79 - 91.83
Chaikin Money Flow
Buy
Level
714.8M
20-day SMA
Buy
Level
$92.30
Relative Strength Index (RSI14)
Buy
Level
58.91
ADX Line
Buy
Level
20.81
Williams %R
Sell
Level
-12.7273
50-day SMA
Buy
Level
$90.79
MACD (12, 26)
Buy
Level
0.62
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
1.4B
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8493)
Sell
CA Score
(Annual)
Level (-0.4148)
Buy
Beneish M-Score
(Annual)
Level (-2.7195)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-1.015)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Stock Forecast FAQ
In the current month, GILD has received 13 Buy ratings 12 Hold ratings, and 0 Sell ratings. The GILD average analyst price target in the past 3 months is $98.92.
-
Where Will Gilead Sciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Gilead Sciences share price will rise to $98.92 per share over the next 12 months.
-
What Do Analysts Say About Gilead Sciences?
Analysts are divided on their view about Gilead Sciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Gilead Sciences is a Sell and believe this share price will drop from its current level to $73.00.
-
What Is Gilead Sciences's Price Target?
The price target for Gilead Sciences over the next 1-year time period is forecast to be $98.92 according to 25 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 12 analysts rate the stock a Hold.
-
Is GILD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Gilead Sciences is a Buy. 13 of 25 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GILD?
You can purchase shares of Gilead Sciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Gilead Sciences shares.
-
What Is The Gilead Sciences Share Price Today?
Gilead Sciences was last trading at $93.89 per share. This represents the most recent stock quote for Gilead Sciences. Yesterday, Gilead Sciences closed at $93.95 per share.
-
How To Buy Gilead Sciences Stock Online?
In order to purchase Gilead Sciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
